Preparation and Drug Release of Aspirin-Loaded PLGA-PEG-PLGA/Montmorillonite Microparticles
Source abstract
Abstract
A polymerization method was used to synthesize biodegradable poly(lactide-co-glycolide)/poly(ethyleneglycol)/poly(lactide-co-glycolide) (PLGA-PEG-PLGA) copolymers. These copolymers were then used to prepare microparticles for encapsulating drug (aspirin). The results of X-ray diffraction (XRD) analysis showed that the montmorillonite (MMT) can be converted into organic montmorillonite (o-MMT). Subsequently, the emulsion solvent evaporation method was used to separately prepare aspirin-loaded PLGA-PEG-PLGA and aspirin-loaded PLGA-PEG-PLGA/o-MMT microparticles. The results of scanning electron microscopy (SEM) showed that microparticle formation was related to the polyvinyl alcohol (PVA) concentration and the proportion of o-MMT. In addition, the ultraviolet-visible (UV-Vis) spectroscopy was conducted to determine the release rate of these microparticles.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · biodegradable polymer synthesis and properties · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. 10.1016/j.colsurfb.2013.01.06610.1016/j.colsurfb.2013.01.066 ↗
2. 10.1016/j.ijbiomac.2013.05.00810.1016/j.ijbiomac.2013.05.008 ↗
3. 10.1016/S0142-9612(00)00115-010.1016/S0142-9612(00)00115-0 ↗
4. 10.1016/j.colsurfb.2012.12.00810.1016/j.colsurfb.2012.12.008 ↗
5. 10.1007/s10934-012-9646-210.1007/s10934-012-9646-2 ↗
6. 10.1016/j.msec.2013.02.02410.1016/j.msec.2013.02.024 ↗
7. 10.1080/00914037.2012.66420810.1080/00914037.2012.664208 ↗
8. 10.1080/00914037.2012.70683910.1080/00914037.2012.706839 ↗
9. 10.1080/00914037.2013.76925410.1080/00914037.2013.769254 ↗
10. 10.1080/03602559.2012.70225510.1080/03602559.2012.702255 ↗
11. 10.1080/03602559.2012.74720710.1080/03602559.2012.747207 ↗
12. 10.1016/j.colsurfb.2013.06.01110.1016/j.colsurfb.2013.06.011 ↗
13. 10.1016/j.colsurfb.2013.03.03910.1016/j.colsurfb.2013.03.039 ↗
14. 10.1080/00914037.2011.64163110.1080/00914037.2011.641631 ↗
15. 10.1080/00914037.2013.76916410.1080/00914037.2013.769164 ↗
16. 10.1080/00914037.2013.76923810.1080/00914037.2013.769238 ↗
17. 10.1080/03602559.2012.70225210.1080/03602559.2012.702252 ↗
18. 10.1080/03602559.2012.69868410.1080/03602559.2012.698684 ↗
19. 10.1002/app.3905110.1002/app.39051 ↗
20. 10.2147/IJGM.S3906510.2147/IJGM.S39065 ↗
21. 10.2147/IJN.S4057910.2147/IJN.S40579 ↗
22. 10.1049/mnl.2010.010710.1049/mnl.2010.0107 ↗
23. 10.2147/IJN.S1890510.2147/IJN.S18905 ↗
24. 10.1002/app.3925510.1002/app.39255 ↗
25. 10.1016/j.eurpolymj.2013.04.03310.1016/j.eurpolymj.2013.04.033 ↗
26. 10.1016/j.msec.2013.02.02010.1016/j.msec.2013.02.020 ↗
27. 10.1016/j.ijpharm.2004.09.02610.1016/j.ijpharm.2004.09.026 ↗
28. 10.1016/j.colsurfb.2013.06.03510.1016/j.colsurfb.2013.06.035 ↗
29. Seema · Int. J. Pharm. Pharmaceut. Sci. · 2013 · 5 · 332